Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
20.8M
-
Shares change
-
+2.96M
-
Total reported value, excl. options
-
$962M
-
Value change
-
+$143M
-
Put/Call ratio
-
3.77
-
Number of buys
-
62
-
Number of sells
-
-62
-
Price
-
$46.28
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2017
165 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2017.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.8M shares
of 207M outstanding shares and own 10.02% of the company stock.
Largest 10 shareholders include Pentwater Capital Management LP (1.99M shares), BB BIOTECH AG (1.51M shares), STATE STREET CORP (1.51M shares), FMR LLC (1.34M shares), BlackRock Inc. (1.28M shares), CREDIT SUISSE AG/ (1.11M shares), Boxer Capital, LLC (1M shares), DISCOVERY CAPITAL MANAGEMENT, LLC / CT (965K shares), Aisling Capital LLC (837K shares), and VANGUARD GROUP INC (756K shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.